Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Vaylen vs Virta Health

Vaylen
Graded #44

Higher grade

vs+18.200000000000003
Virta Health
Graded #336

Lower grade

The verdict

Vaylen takes it — 77.9/100 to 59.7/100.

Vaylen grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vaylen is a pure GLP-1 specialist offering compounded semaglutide ($179/mo), compounded tirzepatide ($239/mo), compounded oral GLP-1 ($259/mo), and brand-name Ozempic, Zepbound, and Wegovy.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVaylen +22
67
45
Dose & formulationVaylen +37
88
51
Clinical oversightVaylen +7
84
77
Labs & monitoringVaylen +6
77
71
FulfillmentVaylen +25
90
65
Contract termsEven
55
55
Vaylen · left barVirta Health · right bar

The numbers

MetricVaylenVirta Health
WeighScore77.9/10059.7/100
GradeC+C
Scorecard rank#44#336
Semaglutide$179/mo (compounded)Not disclosed
Tirzepatide$239/mo (compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
Vaylen

Graded #44 · C+

Strengths

  • Pure GLP-1 specialist — not a multi-category telehealth platform
  • All 50 states coverage with licensed clinicians
  • Both compounded and brand-name options (Ozempic, Wegovy, Zepbound)
  • Oral GLP-1 option (compounded dissolvable tablets) for needle-averse patients
  • LegitScript certified

Where it loses points

  • Compounded semaglutide at $179/mo is mid-range (not the cheapest)
  • Brand-name options at near-retail pricing ($997-$1,086/mo)
Virta Health

Graded #336 · C

Strengths

  • Offers a Responsible Prescribing track with optimized GLP-1 use
  • Clinically monitored medication off-ramp toward nutrition therapy
  • Nutrition-first model shown to rival GLP-1 weight loss (about 13% at 1 year)
  • Provided at no cost to members through employers and health plans
  • Strong evidence base for diabetes reversal and metabolic health

Where it loses points

  • Primarily a nutrition program; GLP-1s are a secondary track
  • Distributed via employers and health plans, no direct cash-pay
  • Deliberately discourages GLP-1 use for most members
  • GLP-1 access depends on the specific program the plan selects

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard